TYRA
Tyra Biosciences, Inc.
$34.32
+4.32%
2026-05-08
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Key Fundamentals
Forward P/E
-13.07
EPS (TTM)
$-2.01
ROE
-39.8%
Profit Margin
0.0%
Debt/Equity
2.24
Price/Book
6.95
Beta
0.79
Market Cap
$1.99B
Avg Volume (10D)
860K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$40.65
60D Low
$24.88
Avg Volume
1.1M
Latest Close
$34.32
Get breakout alerts for TYRA
Sign up for Breakout Scanner to receive daily notifications when TYRA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Tyra Biosciences, Inc. (TYRA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors TYRA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. TYRA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.